Skip to main content
Journal cover image

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.

Publication ,  Journal Article
Kolb, EA; Gorlick, R; Keir, ST; Maris, JM; Kang, MH; Reynolds, CP; Lock, RB; Carol, H; Wu, J; Kurmasheva, RT; Houghton, PJ; Smith, MA
Published in: Pediatr Blood Cancer
June 2015

BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network. In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50 ) of 13.8 nM (range 5.4-25.2 nM). The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine. BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts. No objective responses were observed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

June 2015

Volume

62

Issue

6

Start / End Page

1106 / 1109

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tubulin Modulators
  • Oxadiazoles
  • Oncology & Carcinogenesis
  • Mice
  • Inhibitory Concentration 50
  • Humans
  • Cell Line, Tumor
  • Benzimidazoles
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Kang, M. H., Reynolds, C. P., … Smith, M. A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer, 62(6), 1106–1109. https://doi.org/10.1002/pbc.25329
Kolb, E Anders, Richard Gorlick, Stephen T. Keir, John M. Maris, Min H. Kang, C Patrick Reynolds, Richard B. Lock, et al. “Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 62, no. 6 (June 2015): 1106–9. https://doi.org/10.1002/pbc.25329.
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, et al. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106–9.
Kolb, E. Anders, et al. “Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer, vol. 62, no. 6, June 2015, pp. 1106–09. Pubmed, doi:10.1002/pbc.25329.
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106–1109.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

June 2015

Volume

62

Issue

6

Start / End Page

1106 / 1109

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tubulin Modulators
  • Oxadiazoles
  • Oncology & Carcinogenesis
  • Mice
  • Inhibitory Concentration 50
  • Humans
  • Cell Line, Tumor
  • Benzimidazoles
  • Antineoplastic Agents